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 ABSTRACT 
Myxedema coma, a rare entity with a reported 25-65% mortality had no objective criteria 
for making the diagnosis when we began our study. We developed an objective screening tool 
for myxedema coma to more easily identify patients and examine the best treatment method in 
future prospective studies to reduce the mortality of this entity. We conducted a retrospective 
chart review to find all patients aged ≥ 18 years admitted with myxedema coma from 1/1/2005 
through 6/13/2010 at Indiana University Health Methodist Hospital. Based both on our 
retrospective chart review and on literature-based accounts, we identified 6 criteria to diagnose 
myxedema coma. We identified 10 patients initially diagnosed with myxedema coma and 
established a control group consisting of 13 patients identified with altered mental status and 
elevated TSH levels. The six variables we created for  the screening tool are heart rate, 
temperature, Glasgow coma scale, thyroid stimulating hormone, free T4, and precipitating 
factors. The screening tool has a sensitivity and specificity of about 80%. We ran a logistic 
regression model using the 10 study patients and 13 controls with the 6 variables. No variables 
alone significantly contributed to the model. However, the overall model was highly significant 
(P = 0.012), providing strong support for a scoring system that uses these variables 
simultaneously. This screening tool enables physicians to rapidly diagnose myxedema coma to 
expedite treatment. A more refined diagnostic tool may be used in future clinical studies 
designed to determine the optimal treatment.  
 INTRODUCTION 
Myxedema coma is a rare entity that often presents as a diagnostic challenge due to the 
rarity of the condition and its insidious onset [for reviews see (1-3)]. Unrecognized and 
untreated, the condition is often fatal, with reported mortality approximately 30-50%. A key to 
the diagnosis of myxedema coma is the physician’s in-depth knowledge of the illness, but the ER 
physician or hospitalist receives little guidance. Hampering early recognition of myxedema coma 
is the lack of set criteria for its diagnosis. There is no adequate standard definition of myxedema 
coma. Nor is there a true etiology. The clinical signs that have been associated with the disease 
are numerous, as is the list of abnormal laboratory results (4). Most articles in the medical 
literature agree that myxedema coma is suggested clinically by the presence of altered mental 
status, hypothermia, and identification of a precipitating factor such as cold exposure, sepsis, or 
drugs (2, 5, 6). Biochemically, serum T4 and T3 concentrations are reduced with either elevation 
of thyroid stimulating hormone (TSH) in primary hypothyroidism or low or normal TSH in 
secondary hypothyroidism. However, it is important to emphasize that patients reported in the 
literature to have myxedema coma do not present with all the aforementioned features. Indeed, 
altered mental status without coma is commonly reported in patients with myxedema coma. A 
precipitating factor may be evident in less than 50% of cases (7). The non-specific presenting 
feature of myxedema coma is a complicating factor in making the correct diagnosis, and without 
the diagnosis, treatment cannot be optimized. It is widely acknowledged that the lethal nature of 
this disease demands early recognition and proper treatment, although proper treatment has not 
yet been established. 
In an effort to improve treatment for these patients, we have focused first on defining the 
clinical entity. Our study was prompted by an unexpectedly high number of patients who were 
 admitted to our institution with a diagnosis of myxedema coma in a 5-year period. We conducted 
a retrospective chart review and used these cases to develop an objective screening tool to help 
correctly classify such patients. Our ultimate goal is to reduce the mortality of patients with 
myxedema coma through early recognition and optimal treatment. Our preliminary results were 
presented at the 2011 Endocrine Society meeting (8), and we now present our full study. We 
propose that a future prospective multicenter study be conducted using an objective diagnostic 
tool to determine the optimal treatment for myxedema coma.  
 METHODS 
SETTING AND STUDY DESIGN 
This was a retrospective chart review analyzing all patients aged 18 years and older 
admitted with a diagnosis of myxedema coma between January 1, 2005 and June 13, 2010 at IU 
Health Methodist Hospital. For control subjects, we reviewed charts of patients during that same 
time period who had both an elevated TSH and altered mental status but were not given a 
diagnosis of myxedema coma. 
The data analyzed in this study were retrieved from the medical records department and 
consist of electronic records and paper charts. The access to and analyses of the database were 
approved by the Indiana University Institutional Review Board (IRB) and conforms to relevant 
ethical guidelines for human research.  
All patients with an admitting diagnosis of myxedema coma recorded in their charts 
between January 1, 2005 and June 13, 2010 were identified. During this period of review, 
although a diagnosis of myxedema coma was recorded, a specific ICD-9-CM code for 
myxedema coma was not yet available. Instead, the diagnostic coding for these patients included 
Hypothyroidism (ICD-9-CM codes 243-244.9), Altered Mental Status (ICD-9-CM code 780.97), 
Consciousness Alteration (ICD-9-CM code 780.09), or Coma (ICD-9-CM code 780.01).  The 
demographic characteristics, comprehensive records of history of presenting illness, past medical 
history, home medications, family history, social history, vital signs obtained in the emergency 
department on admission, detailed physical examination, all laboratory data and investigations 
obtained during hospitalization, concomitant co-morbidities, and the course of treatment and 
management in the hospital were all examined (Table 1). After review of the records by two of 
the authors, we re-classified 2 patients admitted with the diagnosis of myxedema coma as not 
 having that disease and two control patients as having myxedema coma. The re-classification 
was based on the clinical expertise of the authors. 
A screening tool for myxedema coma was developed from a set of 6 inclusion criteria 
honed from characteristics found in our patient population and patients from the literature (Table 
2). The criteria were selected in an attempt to minimize the number of criteria needed to make 
the diagnosis of myxedema coma by only including those that are most relevant. This is in 
keeping with our goal of creating an accurate tool that is also expedient. A search of myxedema 
coma in the medical literature, primarily Medline®, resulted in the identification of 365 
manuscripts. Of those, 3 studies were selected because the authors had published patient 
descriptions with enough information to be useful in our screening tool: Dutta et al (9), 
Rodriguez et al (6), and Yamamoto et al (10). Other definitions of myxedema coma from case 
review articles and several case reports were also taken into consideration.  
After developing the six criteria, a score was assigned to each criterion based on the 
observation of our patients and the emphasis of each criterion in the literature, with the most 
weight being given to altered mental status and increased TSH. The intent was to develop 3 
categories of patients based on the criteria that would predict the likelihood of myxedema coma. 
To test our screening tool, we evaluated data on a different set of patients with known 
thyroid disease, as indicated by elevated TSH levels and an admitting diagnosis of altered mental 
status, but who had not been diagnosed with myxedema coma. These patients were admitted 
during the same time period as our study group (Table 3).  
Ten patients with a diagnosis of myxedema coma were used as our study subjects to 
develop the criteria for the screening tool. The 6 criteria used were the Glasgow Coma Scale (11) 
(Table 8) measured on admission, thyroid stimulating hormone (TSH ≥ 15mU/L), free T4 (FT4, 
 < 0.6 ng/dL), hypothermia (temperature less than 95 °F), bradycardia (heart rate less than 60 
beats per minute), and the presence of a precipitating factor (Table 2). 
The scores assigned to each criterion are listed in Table 4. Patients were divided into 3 
groups based on the total scores. If the total score was > 7, we suggested that they had 
myxedema coma; if the score was 5 – 7, we suggested that myxedema coma was likely if no 
other plausible cause was present; and if the score was < 5, we suggested that the patient was 
unlikely to have myxedema coma and another diagnosis should be considered (Table 4). 
The data collected on 13 patients who served as the control group were used in our 
statistical analysis (Table 3).  
 
STATISTICAL ANALYSIS 
Data analysis was performed using R (12) and the ROCR package (13). The ROC 
(Receiver Operating Characteristic) Curve was used to determine the sensitivity and specificity 
of our screening tool (Figure 1). The ROC analysis performed using all 10 patients with a 
diagnosis of myxedema coma and the 13 patients in the control group. A logistic regression 
model using the 23 patients and the variables of heart rate, temperature, Glasgow Coma Score 
(GCS), TSH, FT4, and the presence or absence of illness (such as a precipitating event) or 
disease was performed to validate the relationship between these variables and the diagnosis of 
myxedema coma.   
 RESULTS 
The median age of the study population was 82 years and all were female. They all had a 
GCS of less than 15. Four patients were hypothermic. Six patients were found to be bradycardic. 
Seven patients had a TSH > 30 mU/L. The free thyroxine level was not measured in all patients. 
Five patients had an identifiable precipitating factor. (Table 1) 
The control group of 13 patients (Table 3) admitted with altered mental status and 
elevated TSH had a median age of 70 years. Only seven patients scored a GCS of less than 15 
(including patient 5) despite documented confusion. Confusion itself warrants a score of four out 
of five in the verbal response category of the GCS so that all patients should have had a GCS 
score of no greater than 14. We did not, however, alter the documented GCS scores reported by 
the ER nurses on admission because the ER reported GCS would be used to make the original 
diagnosis. Thus in reality, these 13 patients should have had a GCS score of less than 15. All 
patients had an elevated TSH. Three of the thirteen patients had a TSH > 30 mU/L. None of the 
patients had documented hypothermia. Only one patient was bradycardic. Nine patients had an 
identifiable precipitating factor. The free thyroxine level was obtained in three patients and all 
three were within the normal range of 0.6 – 1.5 ng/dL.  
Using both literature recommendations and examination of our myxedema coma study 
population, we selected the following variables to predict the presence of myxedema coma: 
GCS, TSH, temperature, pulse, and the presence or absence of another illness. While additional 
variables could have been added, we wished to minimize the variables required for the scoring 
tool. With these variables, we ran a logistic regression model using all 23 patients (10 subjects 
and 13 controls). None of these variables alone significantly contributed to the model. However, 
 the overall model itself was highly significant with (P = 0.012). This provides strong support for 
using these variables in our myxedema coma tool scoring system. 
Based on our scoring system, of the ten study patients diagnosed with myxedema coma, 
one patient had definite myxedema coma, seven were in the “Likely” category and two were 
unlikely to have myxedema coma. One of the two patients unlikely to have myxedema coma had 
secondary hypothyroidism. The other patient that was in the unlikely category did not have FT4 
measured or a precipitating factor identified (Table 6). 
Based on our scoring system applied to the control group, two patients were classified 
into the “Likely” Category, while eleven were in the “Unlikely” category. The two patients who 
fell into the likely category had a more plausible diagnosis than myxedema coma. (Table 6) 
The ROC (Receiver Operating Characteristic) Curve was used to determine a cut off 
score to maximize true positive and minimize false positive. We performed the ROC analysis on 
the 23 subjects and controls. The optimal value occurs where the curve is nearest the upper left 
corner (Figure 1A). This point corresponds to a score value of 5 and is associated with a 
sensitivity of about 80% and a specificity of about 80% (1 - specificity = 20%). An area under 
the curve (AUC) of greater than 0.8 suggests the test performs with high accuracy (14), and the 
AUC for the graph is 0.865.  
The value of the scoring system was further supported by using the scoring system alone 
in a regression model to predict myxedema coma. That was also statistically significant with (P = 
0.019). Thus, the scoring system works nearly as well as modeling with all variables.  
We used 2 additional techniques to validate our system. First, we used bootstrapping 
(sampling with replacement) to create an array of 500 samples from the 23 subjects and controls.  
Without having an additional source of subjects to sample, bootstrapping allows us to be sure 
 that a few outliers in our 23 patients did not account for the significant relationship between the 
chosen variables and the outcome. With this array, we ran a separate ROC analysis with similar 
results: The sensitivity and specificity were 0.64 and 1.0, respectively, at a cutoff of 7 for the 
disease. The AUC was 0.87 (data not shown). 
The second technique we used was to apply our model to the 25 patients reported in the 
literature to have myxedema coma for whom there was sufficient data to abstract. This showed 
that our model successfully labeled 24 of the 25 into the “Most Likely” category (Table 5). 
Further, when we included these 25 reported cases with our own 23 subjects and controls, and 
repeated the ROC analysis, we found the model gave a sensitivity of 0.8 and specificity of 1.0 at 
a cutoff of 6 (Fig. 1B).  
 DISCUSSION 
Myxedema is a term suggested by Ord in 1878 to describe a condition with a myriad of 
symptoms related to “mucous oedema” that resulted in vascular and nervous disorders (15). 
Summers, 75 years after Ord, focused on coma as a terminal event of myxedema in 4 patients, all 
of whom had extremely low body temperature (16). Most articles in the literature agree that 
myxedema coma is a form of hypothyroidism with physiological decompensation, suggested 
clinically by the presence of altered mental status, hypothermia, and the identification of a 
precipitating factor such as cold exposure, sepsis or drugs (1, 2, 6, 17). However, myxedema 
coma has not been consistently defined using all the same parameters. Indeed, the mechanisms 
leading to this clinical condition may be different in different individuals. This may reflect the 
tendency of the disease to be a combination of many processes within an individual. This 
combination adds to the complexity of a) making the diagnosis, b) optimizing treatment, and c) 
understanding the increased mortality of the disease.  
Before studying the most effective treatment for myxedema coma, a suitable definition of 
this condition needs to be established. Our study was the first to develop and test an objective 
tool for determining whether or not a patient does indeed have myxedema coma. One aspect of 
the tool that we considered necessary was the ability to make an early assessment with a high 
degree of specificity and sensitivity that could also be done rapidly and with the least amount of 
effort. The need for accurate expediency led us to restrict our criteria to the 6 characteristics that 
are most likely affected in this disease. 
Among our selected criteria is the TSH level of the patient. Although elevated TSH levels 
are common in patients with myxedema coma, it is not a sine qua non. For example, patients 
 with pituitary disease would not have elevated TSH levels but may have myxedema coma as has 
been reported (9). Thus, we have included TSH levels in our screening tool. 
Altered mental status may be manifested as cognitive deterioration, lethargy, confusion, 
or disorientation (1, 18-20). In our study, all our patients (subjects and controls) were 
documented to have altered mental status. However, the ER nurse inaccurately assigned a GCS 
score of 15 to patients who displayed disorientation or confusion. Because this was a 
retrospective analysis and we did not personally examine each patient, we elected to not alter the 
GCS that had been assigned. Nevertheless, when we re-analyzed with an altered the GCS, it did 
not make a significant difference in the outcome. 
According to several authors, hypothermia can be found in virtually all patients; however, 
the body temperature may be normal due to concurrent infection (1, 2). Only 40% of our patients 
had hypothermia. In a study reported by Dutta et al., 15 of 23 patients presented in winter, and 
cold exposure was considered to be a major precipitating factor (9). In 1960, J.H Angel 
suggested that hypothermia itself maybe an indication for immediate treatment with a rapidly 
acting thyroid hormone (21). 
The possibility of a precipitating infection or other acute illness should always be 
considered. Fifty percent of our studied population had an identifiable precipitating factor. 
Indeed, infection was the most common of those factors. A precipitating factor was evident in 
only 34 of 77 cases in an analysis of myxedema coma reported by Forester (7). Sepsis was the 
most common precipitating factor among the 23 patients with myxedema coma in a study 
reported by Dutta et al (9). 
Interestingly, two patients in our study who were diagnosed with myxedema coma had 
subclinical hypothyroidism. A similar observation was recorded in a case report by Mallipedhi et 
 al (5). Thus, myxedema coma with subclinical hypothyroidism may not be extremely rare. Of 
our 10 patients, eight were treated with IV levothyroxine, and two were treated with oral 
levothyroxine. One of the two patients treated with oral levothyroxine had resolution of her 
mental status on the day of admission. Therefore, we reported this as a false positive in our study 
as this patient was likely misdiagnosed with myxedema coma. In addition to this false positive, 
we found our screening tool provided a false negative on a patient with central hypothyroidism 
due to an unusually low TSH. 
We acknowledge that there are limitations in this study. As with any chart review, 
information is a direct extraction from patients’ charts; thus errors and biases may occur. One 
such bias was the documentation of the GCS score. Other biases include the many instances in 
which the precipitating factors were not identified. This, in part, may be because we are 
uncertain of the types or sorts of precipitating factors. For example, is stroke a precipitating 
factor or the real cause of altered mental status in a patient with profoundly elevated TSH and 
low FT4? As for the laboratory data, there were many cases in which the FT4 was not obtained. 
Certainly if the patient were to have secondary hypothyroidism the absence of a FT4 and the 
presence of a “normal” TSH can contribute to a lower sensitivity of our tool.  
Another limitation is the cutoff of 5 for the diagnosis of myxedema coma (Table 2). 
While this value is consistent with the ROC analysis performed on our own 23 subjects, when 
the additional 25 patients from the literature were added to our own 23 to perform a ROC 
analysis, the cutoff was determined to be 6. Clearly an analysis with further cases and controls 
will provide greater confidence in the designated cutoff value for identifying myxedema coma. 
As we begin to understand further the mechanisms that lead to the clinical manifestations 
of thyroid dysfunction, it is clear that a measured TSH or a measured free T4 is inadequate to 
 fully explain the clinical presentation. The complexity of thyroid hormone action at the tissue 
level is influenced by multiple factors at both the genomic and post-genomic level. 
Consequently, there is a spectrum of manifestations of the hypothyroid state. We believe that 
analogous to the widely appreciated Burch and Wartofsky scoring system for thyroid storm (22), 
a scoring system for myxedema coma will help to appropriately diagnose this condition, which is 
a manifestation in part of the degree of hypothyroidism and the influence of multiple other 
factors.  
Our purpose was to create a simple usable tool that would easily allow ER physicians and 
hospitalists to screen for myxedema coma. Since the time our preliminary findings and initial 
myxedema coma screening tool were introduced in 2011 (8), we have become aware of a 
recently published manuscript with a scoring system for myxedema coma that is similar but more 
comprehensive than our own (23). The more involved system includes gastrointestinal findings, 
a list of cardiovascular problems (in addition to bradycardia), and several conditions of metabolic 
disturbance. While a more complicated tool may provide better sensitivity and specificity, we 
believe that the simpler the tool the more likely it will be used. We present our original research 
to allow continued discussion for the creation of a refined diagnostic tool that will then permit a 
future prospective multicenter study to be conducted to determine the optimal treatment for 
myxedema coma.  
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 FIGURE LEGENDS 
Figure 1: Receiver Operating Characteristic (ROC) Curve. ROC analysis of A) all 23 patients 
(subjects and controls) and B) all patients plus an additional 25 patients reported in the literature 
to have myxedema coma. AUC is the area under the curve. Arrows indicate the optimal value of 
sensitivity and specificity.      
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Table 1: Clinical and laboratory findings in 10 patients with myxedema coma 
Patient Age Sex Precipitating 
factors 
GCS Associated  
comorbidities 
TSH   
(mU/L)   
FT4 
(ng/dL) 
Temp 
(°F)  
HR 
(bpm) 
Outcome 
           
1 50/F F - 14 Hypertension, 
Type 2 Diabetes, 
Obstructive Sleep 
Apnea 
 
59.7 0.3 96.8 78 Alive 
2 93 F Urinary Tract 
Infection 
14 Alzheimer’s Dementia, 
Acute renal failure, 
Leukopenia, 
Thrombocytopenia 
 
102.8 - 91.7 52 Died 
3 89 F - 14 Hypertension, 
Chronic Obstructive 
Pulmonary Disease, 
Acute on chronic renal 
failure 
 
140 - 98.2 92 Alive 
4 86 F - 14 Congestive Heart 
Failure, 
Acute on chronic renal 
failure, 
Hypoglycemia, 
Hyponatremia 
 
95.4 - 97.4 43 Alive 
5 66 F - 14 Carvenous sinus 
meningioma, 
Panhypopituitaridism, 
Hyponatremia 
 
0.187 0.7 96.9 95 Alive 
6 86 F Urinary Tract 
Infection 
14 Pancytopenia, 
Chronic kidney disease, 
Hypertension, 
Type 2 Diabetes,  
Alzheimer’s dementia 
9.48 1.2 90.4 45 Alive 
           
7 83 F Aspiration 
Pneumonia 
10 Dementia, 
Hypertension, 
Dysphagia 
 
11.6 - 88.6 44 Alive 
8 82 F Urinary Tract 
Infection 
13 Adrenal insufficiency, 
Acute respiratory 
failure, 
Dysphagia 
 
36.2 0.8 89.6 74 Alive 
9 68 F Primary 
biliary 
cirrhosis 
8 Primary Biliary 
Cirrhosis, 
Septic shock, 
Anemia, 
Gastric ulcers 
 
158 0.2 96.9 54 Alive 
10 44 F - 3 Acute respiratory 
failure 
 
87.8 - 97.5 51 Alive 
 
Abbreviations: GCS, Glascow Coma Score; FT4, Free T4; Temp, Temperature; HR, Heart Rate; bpm, beats per minute 
Table 2. Comparing the percentage of patients with the six criteria used in Myxedema 
Coma screening tool between the literature and our study. 
Criterion Dutta (9) 
(N=23) 
Rodriguez (6) 
(N=11) 
Yamamoto 
(10) 
(N=8) 
Our Study 
(N=10) 
Our Control 
(N=13) 
      
AMS 100% 100% 100% 100% 54% 
 
Hypothermia¹ 
 
Bradycardia² 
 
100% 
 
- 
 
100% 
 
54.54% 
 
75% 
 
87.5% 
 
40% 
 
60% 
 
0% 
 
8% 
 
Elevated TSH 
 
83% 
 
81.81% 
 
100% 
 
90% 
 
100% 
 
Low FT4 or TT4 
 
100% 
 
100% 
 
100% 
 
20% 
 
0% 
 
Precipitating 
Illness³ 
 
 
100% 
 
100% 
 
100% 
 
50% 
 
69% 
Abbreviations: AMS, altered mental status; TSH, thyroid stimulating hormone; FT4, free thyroxine; TT4, total thyroxine.  
¹ Body temperature less than 95°F measured on admission. 
² Heart rate less than 60 beats per minute measured on admission. 
³ Burns, carbon monoxide retention, gastrointestinal hemorrhage, infection, sepsis, medications, stroke, surgery, trauma etc (17) 
 
Table 3: 13 patients admitted with altered mental status and elevated TSH levels 
Patient Age Sex Precipitating 
factors 
GCS Associated 
comorbidities 
TSH  
(mU/L) 
FT4 
(ng/dL) 
Temp 
(°F ) 
HR 
(bpm) 
Outcome 
           
1 62 F - 14 ESRD, 
Congestive Heart 
failure 
12.5 - 100.9 99 Alive 
           
2 75 M Dehydration 15 Chronic renal 
failure, 
Hypertension, 
Hypernatremia 
 
14.857 - 97.9 82 Alive 
3 70 F Urinary Tract 
Infection 
15 Dementia 
 
5.01 0.8 98.1 83 Alive 
           
4 83 M Aspiration 
Pneumonia 
15 Congestive heart 
failure, 
Orthostatic 
hypotension, 
DVT, 
Acute renal 
failure 
46.06 - 97.7 71 Alive 
           
5 64 F Valproic Acid 
Toxicity 
- * Hypertension 
 
 
 
25.516 - 96.7 80 Alive 
6 67 F Urinary Tract 
Infection 
15 Hypertension, 
Acute on chronic 
renal failure, 
Dementia 
 
61.319 - 98.9 56 Alive 
7 51 M Medication  
(marijuana, 
opiates, 
benzodiapezine) 
 
14 Hypotension 21.962 1.1 96.2 60 Alive 
8 75 F - 15 Hypertensive 
emergency, 
ESRD, 
Pulmonary 
hypertension, 
Dementia, 
Constipation 
4.225 0.6 98.2 68 Alive 
           
9 83 F Urinary Tract 
Infection, 
medications  
(Codeine) 
15 Hypertension 6.825 - 97.8 91 Alive 
           
10 81 F Cellulitis 13 ESRD, 
Hypotension, 
Chronic subdural 
hematoma, 
Congestive heart 
failure 
 
8.847 - 97.7 88 Alive 
           
11 78 F Nasal 
Hemorrhage 
14 Hemorrhagic 
shock, 
Esophageal 
cancer, 
Acute respiratory 
failure, 
Cardiac arrest 
 
74.795 - 98.3 123 Died 
12 69 F Pneumonia  8 Septic shock, 
SVT, 
Decubitus ulcers, 
Acute respiratory 
failure, 
Atrial fibrillation 
with RVR, 
Acute renal 
failure, 
Type 2 Diabetes 
5.271 - 101.7 195 Died 
           
13 61 F Medication  
(Benzodiazepine) 
 
14 Hypertensive 
urgency 
8.892 - 98.4 72 Alive 
Abbreviations: ESRD, End stage renal disease; DVT, deep vein thrombosis; SVT, supraventricular tachycardia; RVR, rapid 
ventricular rate.  
* Suspected GCS of 14. 
 
Table 4: Myxedema Coma Screening Tool 
Criterion Score 
GCS  
0 – 10 4 
11-13 3 
14 2 
15 
 
0 
 
TSH  
More than 30 mU/L 2 
Between 15-30 mU/L 1 
  
Low Free T41 1 
Hypothermia2 1 
Bradycardia3 1 
Precipitating event4 1 
Total Scores Category Recommendation 
8 – 10 Most Likely Proceed with treatment 
5 – 7 Likely Treat if there are no other plausible causes 
< 5 Unlikely Consider other diagnosis 
Abbreviations:  GCS, Glasgow Coma Scale; TSH, thyroid stimulating hormone. 
1 Free T4 < 0.6 ng/dL 
2 Body temperature less than 95°F measured on admission. 
3 Heart rate < 60 beats per minute measured on admission. 
4 Burns, carbon monoxide retention, gastrointestinal hemorrhage, infection, sepsis, medications, stroke, surgery,      
trauma etc (17) 
 Table 5: Characteristics of the 13 patients in the control group 
Criterion Number of Patients 
GCS < 15 7 
Elevated TSH 13 
Low FT41 3* 
Hypothermia2 0 
Bradycardia3 1 
Precipitating event4 9 
  
Abbreviations:  GCS, Glasgow Coma Scale; TSH, thyroid stimulating hormone; FT4, free thyroxine. 
1 Free T4 < 0.6 ng/dL 
2 Body temperature less than 95°F measured on admission. 
3 Heart rate less than 60 beats per minute measured on admission. 
4 Burns, carbon monoxide retention, gastrointestinal hemorrhage, infection, sepsis, 
medications, stroke, surgery, trauma etc (17) 
 
*10 patients had no FT4 obtained. 
 
Table 6: Proposed scoring system applied to our 23 subjects 
Patient GCS 
/score 
TSH 
(mU/L) 
/score 
FT4 
(ng/dL) 
/score 
Body 
Temp 
/score 
Pulse 
(bpm)/ 
score 
Precipitating 
event 
/score  
Total 
score 
Myxedema 
coma 
category 
Study 1 14 2 59.7 2 0.3 1 96.8 0 78 0 no 0 5 Likely 
Study 2 14 2 102.7 2 – – 91.7 1 57 1 yes 1 7 Likely 
Study 3 14 2 140.2 2 – – 98.2 0 92 0 no 0 4 Unlikely 
Study 4 14 2 95.4      2 – – 97.4 0 43 1 no 0 5 Likely 
Study 5 14 2 0.19 0 0.7 0 96.9 0 95 0 no 0 2 Unlikely 
               
Study 6 14 2 9.5 0 1.2 0 90.4 1 45 1 yes 1 5 Likely 
Study 7 10 4 11.6 0 – – 88.6 1 44 1 yes 1 7 Likely 
Study 8 13 3 36.2 2 0.8 0 89.6 1 74 0 yes 1 7 Likely 
Study 9 8 4 158.5 2 0.2 1 96.9 0 54 1 yes 1 9  Most likely 
Study 10 3 4 87.8 2 – – 97.5 0 51 1 no 0 7    Likely 
               
Control 1 14 2 12.5 0 – – 100.9 0 99 0 no 0 2 Unlikely 
Control 2 15 0 14.9 0 –  97.7 0 82 0 no 0 0 Unlikely 
Control 3 15 0 5.0 0 0.8 0 98.1 0 83 0 yes 1 1 Unlikely 
Control 4 15 0 46.0 2 – – 97.7 0 71 0 yes 1 3 Unlikely 
Control 5 14 2 25.5 1 – – 96.7 0 80 0 yes 1 4 Unlikely 
               
Control 6 15 0 61.3 2 – – 98.9 0 56 1 yes 1 4 Unlikely 
Control 7 14 2 22.0 1 1.1 0 96.2 0 60 0 no 0 3 Unlikely 
Control 8 15 0 4.2 0 0.6 0 98.2 0 68 0 no 0 0 Unlikely 
Control 9 15 0 6.8 0 – – 97.8 0 91 0 yes 1 1 Unlikely 
Control 10 13 3 8.8 0 – – 97.7 0 88 0 yes 1 4 Unlikely 
               
Control 11 14 2 74.8 2 – – 98.3 0 123 0 yes 1 5 Likely 
Control 12 8 4 5.3 0 – – 101.7 0 195 0 yes 1 5 Likely 
Control 13 14 2 8.9 0 – – 98.4 0 72 0 yes 1 3 Unlikely 
Abbreviations:  GCS, Glasgow Coma Scale; TSH, thyroid stimulating hormone; FT4, free thyroxine. 
Each column represents one of the 6 scoring criteria proposed. The value of that criterion is shown followed by the proposed 
score (in bold). The total score is the sum of each criterion score. The category is the proposed interpretation of the total score. 
 
Table 7: Scoring system applied to 25 patients from the literature diagnosed with 
myxedema coma 
Patient GCS 
/score 
TSH 
(mU/L) 
/score 
FT4 
(ng/dL) 
/score 
Temp 
(ºF) 
/score 
Pulse 
(bpm)/ 
score 
Precipitating 
event 
/score  
Total 
score 
Myxedema 
coma 
category 
1 (10)  
Coma 4 227 2 – – < 95 1 < 60 1 yes 1 9 Most Likely 
2 (10) Semicoma 2 52 2 – – < 95 1 < 60 1 yes 1 7 Likely 
3 (10) Coma 4 52 2 – – > 95 0 < 60 1 yes 1 8 Most Likely 
4 (10) Coma 4 28      1 – – < 95 1 < 60 1 yes 1 8 Most Likely 
5 (10) Semicoma 2 62 2 – – < 95 1 < 60 1 no 0 6 Likely 
               
6 (10) Coma 4 25 1 < 0.2 1 > 95 0 < 60 1 yes 1 8 Most Likely 
7 (10) Somnolence 0 114 2 < 0.2 1 < 95 1 > 60 0 no 0 4 Unlikely 
8 (10) Somnolence 0 127 2 < 0.2 1 < 95 1 < 60 1 yes 1 6 Likely 
9 (5) Coma 4 6.09 0 10.7 0 91.8 1 88 0 yes 1 6 Likely 
10 (24) Drowsy, 
unintelligent 
speech 
2 72 2 – – 82.8 1 40 1 yes 1 7 Likely 
               
11 (25) 9 4 63 2 Undetect
-able 
1 87.3 1 37 1 yes 1 10 Most Likely 
12 (26) Lethargic - 
>apniec 
4 – – – – 96.8 0 <60 - 62  1 yes 1 6 Likely 
13 (27) 8 4 >50 2 – – 95.4 0 54 1 yes 1 8 Most Likely 
14 (28) Drowsy>LIC/ 
intubated 
4 >200 2 <0.3 1 86.2 1 60 0 yes 1 9 Most Likely 
15 (6)  Obtunded 2 51.3 2 0.46 1 94.1 1 39 1 yes 1 8 Most Likely 
               
16 (6) Coma 4 0.43 0 0.25 1 93.9 1 124 0 yes 1 7 Likely 
17 (6) Coma 4 71 2 0.18 1 93.0 1 38 1 yes 1 10 Most Likely 
18 (6) Obtunded 2 2.54 0 0.23 1 94.8 1 104 0 yes 1 5 Likely 
19 (6) Obtunded 2 76.0 2 0.28 1 93.6 1 114 0 yes 1 7 Likely 
20 (6) Coma 4 28 1 0.17 1 94.6 1 38 1 no 0 8 Most Likely 
               
21 (6) Obtunded 2 38 2 0.15 1 95 0 124 0 yes 1 6 Likely 
22 (6) Coma 4 60.6 2 0.15 1 95 0 65 0 yes 1 8  Most Likely 
23 (6) Obtunded 2 153 2 0.15 1 94.6 1 52 1 yes 1 8 Most Likely 
24 (6) Obtunded 2 9.85 0 0.37 1 94.8 1 144 0 yes 1 5 Likely 
25 (6) Obtunded 2 78.2 2 0.5 1 92.5 1 38 1 yes 1 8 Most Likely 
Abbreviations and format are the same as in Table 6. 
Table 8. Glasgow Coma Scalea  
Activity Best response Score 
Eye Opening Spontaneous 4 
 To speech 3 
 To pain 2 
 None 1 
Verbal response Oriented 5 
 Confused  4 
 Inappropriate words 3 
 Incomprehensible sounds 2 
 None 1 
Motor response Obeys 6 
 Localizes pain 5 
 Withdraws from pain  4 
 Abnormal flexion 3 
 Extension 2 
 None 1 a Glasgow Coma Scale used to define coma:  Responses to stimuli are scored based on the patient’s ability to open eyes and obey verbal and motor commands. The responsive score ranges from 3 to 15. A sum ≤ 7 indicates a comatose state.  (9) 
